ENA Respiratory
PrivateLast Round
Series B
Oct 22, 2025
Total Funding Raised
$46.83M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ENA Respiratory operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series B round in October 2025.
ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defence enhancers to combat respiratory viral infections by boosting the body's local innate immune response.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ENA Respiratory Comparables
Compare ENA Respiratory with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NorthLinks Bio | 85% | |
| Leyden Labs | 79% | |
| SaNOtize Research & Development Corp. | 77% |
For institutional investors. Book with your work email.
ENA Respiratory Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 22, 2025 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Aug 29, 2023 | ||||
| Grant | Jan 9, 2023 | ||||
| VC Round | Jun 15, 2021 | ||||
Series A Extension | Sep 28, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ENA Respiratory Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Flu Lab | Series B |
| Minderoo Foundation | VC Round |
| United States Department of Defense | Grant |
| Hostplus Superannuation Fund | Series A Extension |
| Bill & Melinda Gates Foundation | Series B |
| Uniseed | Series A, Series A Extension, Series B, VC Round |
| Stoic Venture Capital | Series A Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 41% MoM.
- Jun 1, 2025
Monthly visitors grew 100% MoM, reaching 1.6K.
For institutional investors. Book with your work email.
ENA Respiratory Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ENA Respiratory's valuation, stock price, and market status.
Is ENA Respiratory a public or private company?
ENA Respiratory is a private company.
What is the current stock price of ENA Respiratory?
ENA Respiratory is a private company, so its shares have no public market price. Caplight tracks ENA Respiratory's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ENA Respiratory worth (valuation)?
Valuation information for ENA Respiratory is not publicly available.
Can I buy ENA Respiratory stock?
ENA Respiratory shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ENA Respiratory's last funding round?
ENA Respiratory's most recent funding round was Series B on October 22, 2025.
Who are the main investors in ENA Respiratory?
Key investors in ENA Respiratory include Minderoo Foundation, Brandon Capital.
Will ENA Respiratory IPO soon?
No public IPO plans have been announced for ENA Respiratory.
How can I track ENA Respiratory secondary market activity?
Caplight tracks bids, offers, and trades in ENA Respiratory's shares on secondary markets.